Literature DB >> 25196912

Urokinase receptor mediates osteoclastogenesis via M-CSF release from osteoblasts and the c-Fms/PI3K/Akt/NF-κB pathway in osteoclasts.

Parnian Kalbasi Anaraki1, Margret Patecki, Sergey Tkachuk, Yulia Kiyan, Hermann Haller, Inna Dumler.   

Abstract

Bone remodeling is a dynamic process based on a fine-tuned balance between formation and degradation of bone. Osteoblasts (OBLs) are responsible for bone formation and bone resorption is mediated by osteoclasts (OCLs). The mechanisms regulating the OBL-OCL balance are critical in health and disease; however, they are still far from being understood. We reported recently that the multifunctional urokinase receptor (uPAR) mediates osteogenic differentiation of mesenchymal stem cells (MSCs) to OBLs and vascular calcification in atherosclerosis. Here, we address the question of whether uPAR may also be engaged in regulation of osteoclastogenesis. We show that uPAR mediates this process in a dual fashion. Thus, uPAR affected OBL-OCL interplay. We observed that osteoclastogenesis was significantly impaired in co-culture of monocyte-derived OCLs and in OBLs derived from MSCs lacking uPAR. We show that expression and release, from OBLs, of macrophage colony-stimulating factor (M-CSF), which is indispensable for OCL differentiation, was inhibited by uPAR loss. We further found that uPAR, on the other hand, controlled formation, differentiation, and functional properties of macrophage-derived OCLs. Expression of osteoclastogenic markers, such as tartrate-resistant acid phosphatase (TRAP) and cathepsin K, was impaired in OCLs derived from uPAR-deficient macrophages. The requirement of uPAR for osteoclastogenesis was further confirmed by immunocytochemistry and in bone resorption assay. We provide evidence that the underlying signaling mechanisms involve uPAR association with the M-CSF binding receptor c-Fms followed by c-Fms phosphorylation and activation of the PI3K/Akt/NF-κB pathway in OCLs. We further show that uPAR uses this pathway to regulate a balance between OCL differentiation, apoptosis, and cell proliferation. Our study identified uPAR as an important and multifaceted regulator of OBL-OCL molecular interplay that may serve as an attractive target in bone disease and ectopic calcification.
© 2014 American Society for Bone and Mineral Research.

Entities:  

Keywords:  BONE MODELING AND CYTOKINES; CELL/TISSUE SIGNALING; ENDOCRINE PATHWAYS; MOLECULAR PATHWAYS; OSTEOBLASTS; OSTEOCLASTS; REMODELING; STROMAL/STEM CELLS

Mesh:

Substances:

Year:  2015        PMID: 25196912     DOI: 10.1002/jbmr.2350

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  20 in total

Review 1.  [Gut microbiota and osteoporosis].

Authors:  Yong-Quan Huang; Tao Jiang; Hai-Tao Su; Yi-Wen Luo; Qiu-Ke Hou
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2016-02-20

2.  Porphyromonas gingivalis-derived RgpA-Kgp Complex Activates the Macrophage Urokinase Plasminogen Activator System: IMPLICATIONS FOR PERIODONTITIS.

Authors:  Andrew J Fleetwood; Neil M O'Brien-Simpson; Paul D Veith; Roselind S Lam; Adrian Achuthan; Andrew D Cook; William Singleton; Ida K Lund; Eric C Reynolds; John A Hamilton
Journal:  J Biol Chem       Date:  2015-05-15       Impact factor: 5.157

Review 3.  Endogenous repair theory enriches construction strategies for orthopaedic biomaterials: a narrative review.

Authors:  Yizhong Peng; Jinye Li; Hui Lin; Shuo Tian; Sheng Liu; Feifei Pu; Lei Zhao; Kaige Ma; Xiangcheng Qing; Zengwu Shao
Journal:  Biomater Transl       Date:  2021-12-28

4.  12-Deoxyphorbol-13-Hexadecanoate Abrogates OVX-Induced Bone Loss in Mice and Osteoclastogenesis via Inhibiting ROS Level and Regulating RANKL-Mediated NFATc1 Activation.

Authors:  Qi He; Junzheng Yang; Delong Chen; Yejia Li; Dawei Gong; Hui Ge; Zihao Wang; Haibin Wang; Peng Chen
Journal:  Front Pharmacol       Date:  2022-06-03       Impact factor: 5.988

5.  Urokinase plasminogen activator and receptor promote collagen-induced arthritis through expression in hematopoietic cells.

Authors:  Sherry Thornton; Harini Raghu; Carolina Cruz; Malinda D Frederick; Joseph S Palumbo; Eric S Mullins; Kasper Almholt; Pernille A Usher; Matthew J Flick
Journal:  Blood Adv       Date:  2017-03-21

6.  TSC-22 inhibits CSF-1R function and induces apoptosis in cervical cancer.

Authors:  Min-Ji Cho; Ji-Yeon Lee; Min-Gwan Shin; Hyun-Ji Kim; Yu-Joung Choi; Seung Bae Rho; Boh-Ram Kim; Ik Soon Jang; Seung-Hoon Lee
Journal:  Oncotarget       Date:  2017-08-16

7.  Osteoblast Hypoxia-Inducible Factor-1α Pathway Activation Restrains Osteoclastogenesis via the Interleukin-33-MicroRNA-34a-Notch1 Pathway.

Authors:  Hui Kang; Kai Yang; Lianbo Xiao; Lei Guo; Changjun Guo; Yufei Yan; Jin Qi; Fei Wang; Bernhard Ryffel; Changwei Li; Lianfu Deng
Journal:  Front Immunol       Date:  2017-10-16       Impact factor: 7.561

8.  The blocking of uPAR suppresses lipopolysaccharide-induced inflammatory osteoclastogenesis and the resultant bone loss through attenuation of integrin β3/Akt pathway.

Authors:  Yosuke Kanno; Akira Ishisaki; Mei Miyashita; Osamu Matsuo
Journal:  Immun Inflamm Dis       Date:  2016-08-02

9.  Ulinastatin Inhibits Osteoclastogenesis and Suppresses Ovariectomy-Induced Bone Loss by Downregulating uPAR.

Authors:  Jun-Ming Huang; Ran-Yue Ren; Yuan Bao; Jia-Chao Guo; Wei Xiang; Xing-Zhi Jing; Jia Shi; Guo-Xiang Zhang; Long Li; Yong Tian; Hao Kang; Feng-Jin Guo
Journal:  Front Pharmacol       Date:  2018-09-07       Impact factor: 5.810

Review 10.  In vitro Models of Bone Remodelling and Associated Disorders.

Authors:  Robert Owen; Gwendolen C Reilly
Journal:  Front Bioeng Biotechnol       Date:  2018-10-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.